Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2005-08-30
2005-08-30
LoGuyader, John L. (Department: 1635)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C536S023100, C536S024310
Reexamination Certificate
active
06936468
ABSTRACT:
The present invention relates to tolerogenic mammalian dendritic cells (DCs) and methods for the production of the tolerogenic DCs. In addition, the present invention provides a method for enhancing tolerogenicity in a host comprising administering the tolerogenic mammalian DCs of the present invention to the host. The tolerogenic DCs of the present invention comprise an oligodeoxyribonucleotide (ODN) which has one or more NF-κB binding sites. The tolerogenic DCs of the present invention may further comprise a viral vector, and preferably an adenoviral vector, which does not affect the tolerogenicity of the tolerogenic DCs when present therein. Enhanced tolerogenicity in a host is useful for prolonging foreign graft survival and for treating inflammatory related diseases, such as autoimmune diseases.
REFERENCES:
patent: 5871728 (1999-02-01), Thomson et al.
patent: 2002/0164311 (2002-11-01), Storm et al.
patent: 9535032 (1995-12-01), None
Lu et al. Genetic enginnering of dendritic cells to express immunosuppressive molecules (viral IL-10, TGF-beta and CTLA4lg). Journal of Leukocyte Biology, 1999 vol. 66:293-296).
Bielinska et al. Regulation of Gene Expression with Double-Stranded Phosphorothioate Oligonucleotides. Science, 1990 vol. 250:997-1000.
Lu et al. Adenoviral delivery of CTLA4lg into myeloid dendritic cells promotes their in vitro tolerogenicity and survival in allogeneic reciepients. Gene Therapy, 1999 vol. 6:554-563.
Xu et al. Prolongation of liver allograft survival by dendritic cells modified with NF-kB decoy oligodeoxynucleotides. World Journal of Gastroenterology, 2004 vol. 10:2361-2368.
Ma et al. Prevention of Diabetes in NOD Mice by Administration of Dendritic Cells Deficient in Nuclear Transcription Factor-kB Activity. Diabetes, 2003 vol. 52:1976-1985.
Bohham et al. Marked Prolongation of Cardiac Allograft Survival by Dendritic Cells Genetically Engineered with NF-kB Oligodeoxyribonucleotide Decoys and Adenoviral Vectors Encoding CTLA4-lg. Journal of Immunology, 2002 vol. 169:3382-3391.
Giannoukakis et al. Prolongation of Cardiac Allograft Survival using Dendritic Cells treated with NF-kB Decoy Oligodeoxyribonucleotides. Molecular Therapy, 2000 vol. 1:430-437.
Morelli et al. Recombinant adenovirus induces maturation of dendritic cells via an NF-KB dependent pathway. Journal of Virology, 2000 vol. 74:9617-9628.
Rea et al. Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subset. Journal Virology, 1999 vol. 73:10245-10253.
Zhong et al. Recombinant adenovirus is an efficient and non-pertubing genetic vecotr for human dendritic cell. European Journal of Immunology, 1999 vol. 29:964-972.
Tillman et al. Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vecotr. Journal of Immunology, 1999 vol. 162:6378-6383.
Flores-Romo In vivo matuation and migration of dendritic cells. Immunology, 2001 vol. 102:255-262.
Liang et al. “Phenotype and allostimulatory function of dendritic cells treated with antisence oligonucleotides targeting CD80 or CD86 mRNA,” Transplantation Proceedings, vol. 33, No. 1-2 p. 235.
Takayama et al. “Transduction of dendritic cell progenitors with a retroviral vector encoding viral interleukin-10 and enhanced green fluorescent protein allows purification of potientially tolerogenic antigen-presenting cells”. Transplantation vol. 68, No. 12, pp. 1903-1909, Dec. 1999.
Thomson et al. “Are dendritic cells the key to liver transplant tolerance?” Immunology Today, vol. 20, No. 1, pp. 27-32, Jan. 1999.
Ma et al., “Dual modifications, NF-κB deficiency and overexpression of IL-10, enance DC tolerogenic activity,” presented at American Transplant Congress 2003, May 30-Jun. 4, Washington, DC.
Bonham et al., “Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NFκB oligonucleotide decoys and adenoviral vectors encoding CTLA4-Ig1,” Journal of Immunology, 2002, 169:3382-3391.
Hirano et al., “Graft hyporeactivity induced by immature donor-derived dendritic cells,”Transplant Proc. 32:260-264 (2000).
Gao et al., “CD40-deficient dendritic cells producing interleukin-10, but not interleukin-12, induc T-cell hyporesponsiveness in vitro and prevent acute allograft rejection,”Immunology 98:159-170 (1999).
Lee et al., “ Cyclosporine A inhibits the expression of costimulatory molecules on in vitro-generated dendritic cells: association with reduced nuclear translocation of nuclear factor kappa B,”Transplantation 68:1255-1263 (1999).
Lu et al., “Genetic engineering of dendritic cells to express immunosuppressive molecules (viral IL-10, TGF-beta, and CTLA4Ig),”J. Leukoc. Biol. 66:293-296 (1999).
Lu et al., “ Adenoviral delivery of CTLA4Ig into myeloid dendritic cells promotes their in vitro tolerogenicity and survival in allogeneic recipients,”Gene Ther. 6:554-563 (1999).
Ranieri et al., “ Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination,”J. Virol. 73:10416-10425 (1999).
Rea et al., “Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subset,”J. Virol. 73:10245-10253 (1999).
Thomson and Lu, “Dendritic cells as regulators of immune reactivity: implications for transplantation,”Transplantation 68:1-8 (1999).
Tuting et al.,“Dendriitc cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity,”J. Gene Med. 1:400-406 (1999).
Banchereau and Steinman, “Dendritic cells and the control of immunity,”Nature 392:245-252 (1998).
Khanna et al., “ Donor bone marrow potentiates the effect of tacrolimus on nonvascularized heart allograft survival: association with microchimerism and growth of donor dendritic cell progenitors from recipient bone marrow,”Transplantation 65:479-485 (1998).
Lee et al.,“Phenotype, function, and in vivo migration and survival of allogeneic dendritic cell progenitors genetically engineered to express TGF-beta,”Transplantation 66:1810-1817 (1998).
Lu et al.Journal of Leukocyte BiologySupplement 2 Abstract#B52 (1998).
Rescigno et al.,“Dendritic cell survival and maturation are regulated by different signaling pathways,”J. Exp. Med. 188:2175-2180 (1998).
Lu et al., “Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival,”Transplantation 64:1808-1815 (1997).
Fu et al., “Costimulatory molecule-deficient dendritic cell progenitors induce T cell hyporesponsiveness in vitro and prolong the survival of vascularized cardiac allografts,”Transplant Proc. 29:1310 (1997).
Fu et al., “Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients,”Transplantation 62:659-665 (1996).
Lu et al., “Induction of nitric oxide synthase in mouse dendritic cells by IFN-gamma, endotoxin, and interaction with allogeneic T cells: nitric oxide production is associated with dendritic cell apoptosis,”J. Immunol. 157:3577-3586 (1996).
Lu et al.,“ Bone marrow-derived dendritic cell progenitors (NLDC 145+, MHC class II+, B7-1dim, B7-2-) induce alloantigen-specific hyporesponsiveness in murine T lymphocytes,”Transplantation 60:1539-1545 (1995).
Rastellini et al.,“ Granulocyte/macrophage colony-stimulating factor-stimulated hepatic dendritic cell progenitors prolong pancreatic islet allograft survival,”Transplantation 60:1366-1370 (1995).
Andrews and Faller, “ A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells,”Nucleic Acids Res. 19:
Giannoukakis Nick
Lu Lina
Robbins Paul David
Baker & Botts LLP
Gibbs Terra C.
LoGuyader John L.
University of Pittsburgh
LandOfFree
Use of tolerogenic dendritic cells for enhancing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of tolerogenic dendritic cells for enhancing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of tolerogenic dendritic cells for enhancing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3523175